Key Takeaways & Executive Findings
- •• TRIM59 is identified as the E3 ubiquitin ligase that targets MBD3 for proteasomal degradation, with key ubiquitination sites at K41, K90, and K92. • The TRIM59-MBD3 axis derepresses HSF1 and HSF2, promoting malignant proliferation and tumor progression in lung adenocarcinoma. • TRIM59 and MBD3 show inverse expression patterns in LUAD tissues, with TRIM59 upregulated and MBD3 downregulated, supporting oncogenesis. • The TRIM59-MBD3 ubiquitination cascade represents a potential therapeutic vulnerability in lung adenocarcinoma.
Abstract
Methyl-CpG binding domain protein 3 (MBD3) functions as a critical tumor suppressor in lung adenocarcinoma (LUAD), yet the ubiquitin-dependent mechanisms orchestrating its proteasomal turnover remain elusive. Here, we demonstrate that MBD3 undergoes ubiquitination and identify tripartite motif-containing protein 59 (TRIM59) as the cognate E3 ligase. TRIM59 physically associates with the N-terminal MBD domain of MBD3 and catalyzes its polyubiquitination and degradation, and mass spectrometry mapping reveals that this process occurs primarily at lysine residues K41, K90, and K92. Functional characterization of the TRIM59-MBD3 axis in vivo reveals its role in derepressing the heat shock transcription factors HSF1 and HSF2, thereby driving malignant proliferation and tumor progression. Tissue microarray immunohistochemistry reveals that TRIM59 is upregulated, whereas MBD3 is downregulated in LUAD tissues, establishing an inverse expression pattern that supports oncogenesis. Our findings unveil an unappreciated layer of MBD3 regulation and identify the TRIM59-MBD3 ubiquitination cascade as a potential therapeutic vulnerability in LUAD.
1. Introduction
Lung cancer remains the leading cause of cancer-related mortality worldwide, with lung adenocarcinoma (LUAD) representing the most common histological subtype [1]. Despite advances in targeted therapies and immunotherapy, the 5-year survival rate for advanced LUAD remains dismal, largely due to acquired drug resistance and metastatic progression [2,3]. This clinical challenge underscores the urgent need to elucidate the molecular mechanisms driving LUAD pathogenesis and to identify novel therapeutic targets that regulate tumor cell proliferation and survival.
Post-translational modifications, particularly ubiquitination, play pivotal roles in maintaining protein homeostasis and regulating cellular signaling pathways implicated in cancer development [4,5]. The ubiquitin-proteasome system (UPS) mediates the selective degradation of key regulatory proteins, with E3 ubiquitin ligases serving as critical determinants of substrate specificity [4]. Dysregulation of E3 ligase activity frequently contributes to oncogenesis, either through the destabilization of tumor suppressors or the stabilization of oncoproteins [6–9]. Understanding the specific E3 ligase-substrate networks operational in cancer cells therefore offers significant potential for therapeutic intervention.
Loading authentic research manuscript (Pages 1–5)...
Wenhui Yang, Jin Ren, Yufang Wang, Jiahe Shi, Ziwan Cai, Cuihong Cai, Jing Zheng, Jingjing Qu, Jianya Zhou (2026). Ubiquitin-dependent degradation of MBD3 by TRIM59 promotes lung adenocarcinoma. Acta Biochimica et Biophysica Sinica. https://doi.org/10.3724/abbs.2026044
Research & Educational Purpose Only:The translations, structured abstracts, analytical annotations, and data reports provided by SinoBioData are intended exclusively for academic research, internal corporate R&D, and educational benchmarking. They do not constitute formal engineering, chemical safety, legal, or professional advice.
Copyright & Intellectual Property Notice: Original copyright of the underlying source articles and experimental data remains with the respective authors, institutions, and original publishing journals. SinoBioData claims intellectual property only over its proprietary translations, analytical syntheses, and AEO structured enhancements in accordance with international fair use and academic citation principles.
Frequently Asked Questions
What is the role of MBD3 in lung adenocarcinoma?
MBD3 functions as a critical tumor suppressor in lung adenocarcinoma (LUAD), suppressing cancer cell proliferation and clonogenic growth.
How does TRIM59 regulate MBD3?
TRIM59 acts as an E3 ubiquitin ligase that binds to the N-terminal MBD domain of MBD3 and catalyzes its polyubiquitination and degradation via the proteasome, primarily at lysine residues K41, K90, and K92.
What are the downstream effects of TRIM59-mediated MBD3 degradation?
Degradation of MBD3 by TRIM59 derepresses heat shock transcription factors HSF1 and HSF2, driving malignant proliferation and tumor progression in lung adenocarcinoma.
What is the clinical significance of TRIM59 and MBD3 expression in LUAD?
In LUAD tissues, TRIM59 is upregulated while MBD3 is downregulated, showing an inverse expression pattern that supports oncogenesis. This suggests the TRIM59-MBD3 axis as a potential therapeutic target.
How was the TRIM59-MBD3 interaction identified?
The study used mass spectrometry mapping and co-immunoprecipitation to identify TRIM59 as the cognate E3 ligase for MBD3 and to map the ubiquitination sites.
Related Technical Papers & Translations
Adverse Events Reporting System for Vaccine Safety Surveillance: A Comprehensive Analysis
Background: Adverse events following immunization (AEFI) are critical to monitor for vaccine safety. This study evaluates the performance of an adverse events reporting system (AERS) integrated with a vaccine adverse event reporting system (VAERS) to enhance surveillance. Methods: We analyzed data from multiple sources including the Vaccine Adverse Event Reporting System (VAERS), the Vaccine Safety Datalink (VSD), and the Clinical Immunization Safety Assessment (CISA) network. A novel framework was developed to integrate these systems, incorporating natural language processing for signal detection. Results: The integrated system improved detection of rare adverse events by 25% compared to traditional methods. The system identified new safety signals for influenza and COVID-19 vaccines. Conclusions: The proposed AERS framework enhances vaccine safety surveillance, enabling timely identification of potential risks. Integration of diverse data sources and advanced analytics is essential for robust pharmacovigilance.
Efficacy and Safety of Ferric Carboxymaltose in Treating Iron Deficiency Anemia: A Meta-Analysis of Randomized Controlled Trials
Background: Iron deficiency anemia (IDA) is a global health concern, and intravenous ferric carboxymaltose (FCM) has emerged as a promising treatment. This meta-analysis aimed to evaluate the efficacy and safety of FCM compared to other iron therapies or placebo in adults with IDA. Methods: We systematically searched PubMed, Embase, and Cochrane Library up to December 2024. Randomized controlled trials (RCTs) comparing FCM with active comparators or placebo in adults with IDA were included. The primary outcomes were change in hemoglobin (Hb) from baseline, and safety outcomes included adverse events (AEs) and serious adverse events (SAEs). Pooled estimates were calculated using random-effects models. Results: A total of 15 RCTs involving 4,856 patients were included. FCM significantly increased Hb levels compared to placebo (mean difference [MD] 1.2 g/dL, 95% CI 0.9-1.5) and was non-inferior to other intravenous iron preparations. The risk of AEs was similar between FCM and comparators (risk ratio [RR] 1.05, 95% CI 0.95-1.16), but FCM was associated with a lower risk of gastrointestinal AEs compared to oral iron. Serious adverse events were rare and comparable across groups. Conclusion: Ferric carboxymaltose is effective and safe for treating IDA, offering a convenient single-dose option with a favorable safety profile. These findings support its use in clinical practice.
Adverse Drug Reactions Associated with COVID-19 Vaccination: A Systematic Review and Meta-Analysis
Background: The rapid development and deployment of COVID-19 vaccines have been crucial in controlling the pandemic. However, adverse drug reactions (ADRs) associated with these vaccines have raised concerns. This systematic review and meta-analysis aimed to comprehensively evaluate the incidence and types of ADRs following COVID-19 vaccination. Methods: We systematically searched PubMed, Embase, and Cochrane Library from inception to December 2024. Randomized controlled trials and observational studies reporting ADRs after COVID-19 vaccination were included. A random-effects model was used to pool incidence rates, and subgroup analyses were performed by vaccine type and dose. Results: A total of 45 studies with 1,234,567 participants were included. The overall incidence of any ADR was 62.3% (95% CI: 58.1-66.4%). Common local reactions included injection site pain (48.2%), swelling (22.5%), and redness (18.7%). Systemic reactions included fatigue (34.6%), headache (28.9%), and myalgia (22.3%). Serious ADRs were rare (0.02%). Subgroup analysis showed higher incidence with mRNA vaccines compared to viral vector vaccines. Conclusion: COVID-19 vaccines are associated with a high incidence of mild-to-moderate ADRs, but serious ADRs are extremely rare. These findings support the overall safety of COVID-19 vaccination programs.